Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 2, Number 4—October 1996

New Vaccines for the Prevention of Pneumococcal Infections

Helena KäyhtyComments to Author  and Juhani Eskola
Author affiliations: National Public Health Institute, Helsinki, Finland

Main Article

Table 1

Pneumococcal conjugate vaccines in phase-II and phase-III trials

Vaccine Serotype Carrier Manufacturer
PncCRM 4, 6B, 9V, 14, 18C, 19F, 23F CRM197 Wyeth-Lederle Vaccines and Pediatrics
PncD 3, 4, 6B, 9V, 14, 18C, 19F, 23 Diphtheria toxoid Connaught Laboratories
PncT 3, 4, 6B, 9V, 14, 18C, 19F, 23 Tetanus toxoid Pasteur Merieux Serums & Vaccins
PncOMPC 4, 6B, 9V, 14, 18C, 19F, 23F Meningococcal OMPC Merck Research Laboratories

CRM = CRM197, a nontoxic variant of diphtheria toxin; D = diphtheria toxoid; T = tetanus toxoid; OMPC = outer membrane protein complex

Main Article

Page created: December 21, 2010
Page updated: December 21, 2010
Page reviewed: December 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.